Literature DB >> 702579

Alternative pathway activation in sickle cell disease and beta-thalassemia major.

A C deCiutiis, C M Peterson, M J Polley, L J Metakis.   

Abstract

Total hemolytic complement activity (CH50), immuno-electrophoretic conversion of Factor B (C3PA), and of C3 were studied in 16 patients with sickle cell disease in a steady state, eight patients in crisis, and ten patients with β-thalassemia major anemia maintained on a constant transfusion regimen. Patients with sickle cell disease in a steady state have moderatley 56 (percent) depressed conversion of Factor B in addition to markedly decreased conversion of C3 in four of ten patients. One of the three sickle cell patients and two of the four thalassemia patients with low C3 conversion levels have died subsequent to the studies. The combination of chronically decreased Factor B conversion in the face of markedly decreased C3 conversion may make these patients occasionally vulnerable to overwhelming infection analagous to the situation seen in postsplenectomy cases.

Entities:  

Mesh:

Year:  1978        PMID: 702579      PMCID: PMC2537184     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  22 in total

1.  Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation.

Authors:  J A Winkelstein; H S Shin; W B Wood
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

2.  Bactericidal and opsonic properties of C4-deficient guinea pig serum.

Authors:  R K Root; L Ellman; M M Frank
Journal:  J Immunol       Date:  1972-09       Impact factor: 5.422

3.  Diplococcus pneumoniae infections in children with sickle cell anemia.

Authors:  R A Seeler; W Metzger; M A Mufson
Journal:  Am J Dis Child       Date:  1972-01

4.  Deficiency of pneumococcal serum opsonizing activity in sickle-cell disease.

Authors:  J A Winkelstein; R H Drachman
Journal:  N Engl J Med       Date:  1968-08-29       Impact factor: 91.245

Review 5.  The complement system of man (second of four parts).

Authors:  S Ruddy; I Gigli; K F Austen
Journal:  N Engl J Med       Date:  1972-09-14       Impact factor: 91.245

Review 6.  Progress in immunology. Syndromes of diminished resistance to infection.

Authors:  C A Janeway
Journal:  J Pediatr       Date:  1968-06       Impact factor: 4.406

7.  Sodium cyanate as a potential treatment for sickle-cell disease.

Authors:  P N Gillette; C M Peterson; Y S Lu; A Cerami
Journal:  N Engl J Med       Date:  1974-03-21       Impact factor: 91.245

8.  The importance of underlying disease in patients with gram-negative bacteremia.

Authors:  M A Freid; K L Vosti
Journal:  Arch Intern Med       Date:  1968-05

9.  An abnormality of the alternate pathway of complement activation in sickle-cell disease.

Authors:  R B Johnston; S L Newman; A G Struth
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

10.  Iron metabolism, sickle cell disease, and response to cyanate.

Authors:  C M Peterson; J H Graziano; A de Ciutiis; R W Grady; A Cerami; M Worwood; A Jacobs
Journal:  Blood       Date:  1975-10       Impact factor: 22.113

View more
  7 in total

Review 1.  Development of complement therapeutics for inhibition of immune-mediated red cell destruction.

Authors:  Karina Yazdanbakhsh
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

Review 2.  Management of hemolytic transfusion reactions.

Authors:  Jeanne E Hendrickson; Ross M Fasano
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients.

Authors:  R H Wang; G Phillips; M E Medof; C Mold
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

4.  Restoration by normal human immunoglobulin G of deficient serum opsonization for Streptococcus pneumoniae in sickle cell disease.

Authors:  A B Bjornson; J S Lobel; P I Magnafichi; B C Lampkin
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

Review 5.  Heme on innate immunity and inflammation.

Authors:  Fabianno F Dutra; Marcelo T Bozza
Journal:  Front Pharmacol       Date:  2014-05-27       Impact factor: 5.810

Review 6.  Complement in Sickle Cell Disease: Are We Ready for Prime Time?

Authors:  Eleni Gavriilaki; Efthymia Vlachaki; Christos Varelas; Athina Tampaki; Ioanna Sakellari; Αchilles Anagnostopoulos
Journal:  J Blood Med       Date:  2021-03-23

Review 7.  Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs.

Authors:  Marcelo T Bozza; Viktória Jeney
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.